3 Health Services Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,662 as of Friday, May 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,201 issues advancing vs. 1,742 declining with 169 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Intuitive Surgical ( ISRG), down 1.7%, Agilent Technologies ( A), down 1.1%, Catamaran ( CTRX), down 1.0%, Humana ( HUM), down 0.7% and Boston Scientific ( BSX), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bruker ( BRKR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bruker is down $0.39 (-1.8%) to $20.96 on light volume. Thus far, 243,206 shares of Bruker exchanged hands as compared to its average daily volume of 778,500 shares. The stock has ranged in price between $20.82-$21.43 after having opened the day at $21.30 as compared to the previous trading day's close of $21.35.

Bruker Corporation, together with its subsidiaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Scientific Instruments, and Energy & Supercon Technologies. Bruker has a market cap of $3.6 billion and is part of the health care sector. Shares are up 8.0% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Bruker a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Bruker as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Bruker Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Opko Health ( OPK) is down $0.30 (-3.4%) to $8.54 on light volume. Thus far, 812,424 shares of Opko Health exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $8.52-$8.86 after having opened the day at $8.85 as compared to the previous trading day's close of $8.84.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.7 billion and is part of the health care sector. Shares are up 4.7% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Align Technology ( ALGN) is down $1.16 (-2.1%) to $53.96 on average volume. Thus far, 566,280 shares of Align Technology exchanged hands as compared to its average daily volume of 937,400 shares. The stock has ranged in price between $53.76-$55.33 after having opened the day at $54.99 as compared to the previous trading day's close of $55.12.

Align Technology, Inc. operates as a medical device company primarily in the United States and internationally. Align Technology has a market cap of $4.3 billion and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Align Technology a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Align Technology Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

European Automakers Gain on Reports China Mulling Auto Tariff Reduction

European Automakers Gain on Reports China Mulling Auto Tariff Reduction